Treatment for acute lymphocyte leukemia儿童急性淋巴细胞白血病临床分型诱导治疗缓解后治疗支持治疗1 概述rn白血病是造血系统恶性增生性疾病,是造血干细胞在分化过程中于某一阶段分化阻滞、凋亡障碍并恶性增殖的疾病.近30年来白血病的基础研究和临床疗效有了长足的进步和发展,从70年代以来,特别是80年代以来,小儿急性白血病...
Table 2. Subtypes of Cells from G-CSF-Primed Bone Marrow and PBSC Infused for Patients with Acute Leukemia Receiving HLA-Mismatched/Haploidentical HSCT Cell TypeBMPBSCTotal MNC (×108/ kg) 3.7 (0.31-12.2) 4.9 (0.4-12.2) 7.9 (3.1-14.8) CD34+ (×106/ kg) 1.1 (0.09-8.2) 1.3 (0.1-5.9...
Medicine, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA Abstract: Acute myeloid leukemia (AML) is a hematologic malignancy that carries a poor prognosis and has garnered few treatment advances in the last few decades. ...
acute myeloid leukemiadecitabineelderlyhypomethylationIntroduction: Intensive chemotherapy remains the only therapeutic option that provides a reasonable chance of long-term survival for adults with acute myeloid leukemia (AML), particularly for those younger than 60 years of age. However, the vast majority...
Information arising from next generation sequencing of leukemia genome has shed important light on the heterogeneous and combinatorial driver events in acute myeloid leukemia (AML). It has also provided insight into its intricate signaling pathways operative in the disease pathogenesis. These have also ...
New Assay Could Revolutionize Detection and Treatment of Acute Myeloid Leukemia
New Assay Could Revolutionize Detection and Treatment of Acute Myeloid Leukemia
Treatment of acute leukemia in adults. The goal of therapy for young adults with de novo acute myeloid leukemia is cure. Seventy percent or more of young adults achieve initial remission, and 30... C A,Linker - 《Current Opinion in Oncology》 被引量: 17发表: 1992年 Peripheral blood haploi...
said, "Our research highlighted an additional mode of action for the treatment known as eprenetapopt opening up its potential to work in a broader group of acute myeloid leukemia (AML) andmyelodysplastic syndrome(MDS) patients.
Acute myeloid leukemia (AML) is the most frequent form of leukemia in adults. The disease develops very rapidly, and has a very poor prognosis, with an average overall 5-year survival rate of 29% with standard therapy. Immunotherapy has led to significant advances in the treatment of several ...